Calcium and vitamin D are essential. That part is not in dispute. The leap comes next: if a nutrient matters, routine supplements should prevent falls and fractures. A large BMJ review suggests they usually do not.
That matters well beyond the supplement aisle. Clinicians, researchers, prevention services and healthy-ageing companies all have to decide whether they are solving a defined problem—or relying on an intervention because it feels familiar and plausible.
What the review found
The review combined 69 randomized trials involving 153,902 adults. It compared calcium, vitamin D, or the two together with placebo or no treatment. People receiving drug treatment for osteoporosis were excluded. Most participants lived in the community, and most were not at high risk of fractures or falls. [1]
For any fracture, calcium alone produced a risk ratio of 0.91, with a 95% confidence interval from 0.81 to 1.01. Vitamin D alone produced a risk ratio of 1.00 (0.95 to 1.06). Combined calcium and vitamin D produced a statistically significant ratio of 0.91 (0.84 to 0.99), but the estimated absolute difference was about one fewer person with a fracture per 100 treated. For hip fractures, the absolute difference was about three fewer per 1,000. The authors judged these differences below their thresholds for a clinically important benefit. [1]
None of the three strategies significantly reduced falls. Across the review, the certainty of evidence was generally moderate to high, although individual trials varied in quality. [1]
A significant result can still be small
Combined calcium and vitamin D did reach statistical significance. On paper, that sounds decisive. In absolute terms, the benefit was modest and was influenced substantially by one trial in a very-high-risk population. The review team had defined what would count as clinically meaningful before interpreting the results, although those thresholds came from expert consensus rather than patient input. [1]
So the conclusion is deliberately narrow. Routine supplementation is not a strong general strategy for preventing fractures and falls in the populations studied. That is the claim supported by the evidence—no more and no less.
Where the evidence stops
The review was not designed to assess treatment of a diagnosed deficiency. It excluded people using osteoporosis drugs, for whom calcium and vitamin D are often prescribed within a wider treatment plan. The results may also not apply directly to people with specific bone disorders or long-term corticosteroid use. Evidence was more limited for some outcomes in high-risk groups and residents of care facilities. [1]
Current osteoporosis guidance therefore still favours individual assessment. It recommends food as the preferred calcium source and targeted supplementation when intake is insufficient in people at risk of osteoporosis or fragility fracture, rather than treating supplements as a universal substitute for evaluation. [4]
These categories matter. Correcting a deficiency or supporting osteoporosis treatment is not the same intervention as routine supplementation for general prevention. Put everything under a broad “bone health” label and the clinical purpose quickly gets lost.
What this changes in practice
Falls are rarely one-variable problems. Balance, strength, medications, blood-pressure changes, vision and the home environment can all play a part. Guidelines therefore emphasize progressive balance and functional exercise, with broader assessment for people at high risk. A useful pathway connects nutritional assessment with medication review, physical training and referral instead of asking one product to do all the work. [3]
Researchers still have important gaps to close in higher-risk populations and care settings. Entrepreneurs and service providers face a simpler test: plausibility is not an outcome. A product or programme that claims fewer falls or fractures has to demonstrate exactly that in the population it intends to serve. [1,2]
Four questions worth asking
What is the indication? Who is the intended population? Does the intervention address the relevant risk? And what outcome has actually been demonstrated? Deficiency treatment, osteoporosis support and general prevention should not share one claim. Biomarkers or engagement should not quietly become evidence of fewer falls or fractures.
Calcium and vitamin D still matter. The mistake is to confuse biological importance with proof that routine supplements prevent falls. Better work begins where that shortcut ends.